Patient-reported outcomes of migraine treatment with erenumab: results from a national patient survey

[1] Noseda R(2013)Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain Pain 154 S44-53

[2] Burstein R(2013)Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II) Headache 53 644-655

[3] Blumenfeld AM(2017)Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis Cephalalgia 37 470-485

[4] Bloudek LM(2015)Adherence to oral migraine-preventive medications among patients with chronic migraine Cephalalgia Int J Headache 35 478-488

[5] Becker WJ(2019)Physician and patient preferences for dosing options in migraine prevention J Headache Pain 20 50-753

[6] Hepp Z(2006)Migraine prevention: what patients want from medication and their physicians (a headache specialty clinic perspective) Headache 46 750-33

[7] Dodick DW(2009)Migraine in the triptan era: lessons from epidemiology, pathophysiology, and clinical science Headache 49 S21-59

[8] Varon SF(2018)A review of monoclonal antibody therapies and other preventative treatments in migraine Headache J Head Face Pain 58 48-484

[9] Hepp Z(2020)Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy J Headache Pain 21 32-2562

[10] Dodick DW(2020)Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center Neurol Sci 41 483-506

[1] Noseda R(2013)Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain Pain 154 S44-53

[2] Burstein R(2013)Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II) Headache 53 644-655

[3] Blumenfeld AM(2017)Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis Cephalalgia 37 470-485

[4] Bloudek LM(2015)Adherence to oral migraine-preventive medications among patients with chronic migraine Cephalalgia Int J Headache 35 478-488

[5] Becker WJ(2019)Physician and patient preferences for dosing options in migraine prevention J Headache Pain 20 50-753

[6] Hepp Z(2006)Migraine prevention: what patients want from medication and their physicians (a headache specialty clinic perspective) Headache 46 750-33

[7] Dodick DW(2009)Migraine in the triptan era: lessons from epidemiology, pathophysiology, and clinical science Headache 49 S21-59

[8] Varon SF(2018)A review of monoclonal antibody therapies and other preventative treatments in migraine Headache J Head Face Pain 58 48-484

[9] Hepp Z(2020)Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy J Headache Pain 21 32-2562

[10] Dodick DW(2020)Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center Neurol Sci 41 483-506